Finding Zepbound (Tirzepatide) Clinics Near You in 2026: A Practical Guide
Medically Reviewed by
Board Certified Endocrinologist
Published
Nov 20, 2025
Last Reviewed
Mar 17, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Where to Find Zepbound Prescribers
Zepbound can be prescribed by a range of healthcare providers: primary care physicians, endocrinologists, obesity medicine specialists, and increasingly through telehealth weight loss platforms. The American Board of Obesity Medicine (ABOM) maintains a provider directory that can help you find specialists in your area. Many patients find that telehealth platforms offer faster access and more streamlined prior authorization processes.
Insurance Coverage in 2026
Zepbound insurance coverage has expanded significantly since its November 2023 approval but remains inconsistent. Most commercial plans now cover it with prior authorization requiring BMI documentation and comorbidity evidence. Medicare coverage remains limited to patients with type 2 diabetes (via Mounjaro, the diabetes-indicated formulation). Eli Lilly offers a savings program where eligible commercially insured patients can pay as little as $25/month.
Cash-Pay and Savings Options
For patients without insurance coverage, Eli Lilly's LillyDirect program offers Zepbound starting at approximately $399/month for cash-pay patients — significantly below the list price of $1,060/month. Compounded tirzepatide may be available from some pharmacies at lower prices, but quality and consistency vary. The FDA has warned against using unregulated sources.
Supply and Availability Status
Zepbound experienced significant supply constraints in 2024. As of early 2026, supply has improved substantially, with most pharmacies able to fill prescriptions within 1–2 weeks. Some dose strengths may occasionally be on backorder. Your pharmacy or prescriber can check real-time availability.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Continue Your GLP-1 Research
Doctor Prescribed Semaglutide Cost Without Insurance: Complete 2026 Guide
Access & Cost · 9 min read
Who Qualifies for GLP-1 Injections? BMI Thresholds, Medical Criteria, and the Gray Areas
Getting Started · 10 min read
Tirzepatide vs. Semaglutide at 72 Weeks: A Head-to-Head Analysis of the Data
Drug Comparison · 11 min read
